featured
Outcomes of Women With HR+/HER2− Advanced Breast Cancer Receiving Gedatolisib Combined With Palbociclib and Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Lancet Oncol 2024 Apr 01;25(4)474-487, RM Layman, HS Han, HS Rugo, EM Stringer-Reasor, JM Specht, EC Dees, P Kabos, S Suzuki, SC Mutka, BF Sullivan, I Gorbatchevsky, R WesolowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.